Cardiac Sarcoidosis is an infiltrative inflammatory disease that can silently damage the conduction system and myocardium, leading to heart block, ventricular arrhythmias, heart failure, or sudden death. This session focuses on recognizing clinical red flags—unexplained AV block in younger adults, idiopathic ventricular tachycardia, or cardiomyopathy with patchy involvement—and building a structured diagnostic approach. Participants will explore how to combine clinical history, ECG, echocardiography, cardiac MRI, PET imaging, and tissue diagnosis when feasible. The aim is to help clinicians suspect and detect cardiac sarcoid early enough to prevent irreversible damage and life-threatening events.

Because presentations are diverse, many clinicians search for a cardiology conference to clarify diagnostic pathways and treatment strategies. This session reviews typical imaging patterns on MRI and FDG-PET, the relationship between cardiac and extracardiac sarcoidosis, and the role of biopsy from lymph nodes, lung, or endomyocardial tissue. Attendees will learn how to distinguish active inflammation from established scar, and how this distinction guides decisions about immunosuppression, device implantation, and ongoing surveillance. Case-based discussions highlight scenarios such as recurrent syncope, sustained VT, or rapidly progressive AV block in patients with known or suspected sarcoid.

A major theme is comprehensive management of granulomatous myocarditis within multidisciplinary teams. Participants will examine steroid-based regimens, steroid-sparing agents, and strategies for monitoring treatment response using symptoms, biomarkers, and serial imaging. The session addresses when to recommend ICD implantation for primary or secondary prevention, how to manage patients with CRT needs, and how to approach ablation in the context of active or burned-out disease. Collaboration with pulmonology, rheumatology, and radiology is emphasized to ensure consistent care across organ systems.

The session also tackles long-term follow-up and patient counselling. Attendees will discuss how to communicate prognosis, address concerns about immunosuppressive side effects, and set expectations for monitoring frequency. By the end, clinicians will have a structured framework for recognizing cardiac sarcoidosis, selecting appropriate investigations, and delivering individualized therapy that balances inflammation control, arrhythmia prevention, and quality of life.